London, UK (PRWEB) January 10, 2012
Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant strains continue to emerge, underscoring the need for additional novel mechanism inhibitors that will offer expanded therapeutic options in the clinic.
New research report “Competitor Analysis: HIV Small Molecule Therapeutics” worked out by La Merie Publishing has been recently published by Market Publishers Ltd.
Title: Competitor Analysis: HIV Small Molecule Therapeutics
Published: December, 2011
Price: US$ 642
The report presents a competitor evaluation in the field of marketed products and R&D projects of HIV small molecule therapeutics. It is also supplemented with a list of company-specific product portfolios and R&D pipelines of HIV small molecule therapeutics.
Competitor projects are listed in a tabular format providing information on:
- drug codes;
- target/mechanism of action;
- class of compound;
- product category;
- R&D stage;
- additional comments with a hyperlink leading to the source of information.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Nucleotide Reverse Transcriptase Inhibitor (NtRTI)
HIV Protease Inhibitors
HIV Integrase Inhibitors
HIV Fusion & Entry Inhibitors
HIV Maturation Inhibtors
Dual Combination Drugs
Triple Combination Drugs
Quadruple Combination Drugs
About La Merie
More new competitive intelligence reports and other studies by the publisher can be found at La Merie Publishing page.